ASX:MDT releasing Q4 and full-year fiscal 2026 results, delivering its highest annual organic revenue growth in 10 years and boosting its cash dividend. Positive sentiment was also bolstered by key FDA regulatory submissions for its Hugo robotic-assisted surgery system.
You're not a member! Trial today
